Cargando…

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib

Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrales, Luis, Nogueira, Amanda, Passiglia, Francesco, Listi, Angela, Caglevic, Christian, Giallombardo, Marco, Raez, Luis, Santos, Edgardo, Rolfo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329017/
https://www.ncbi.nlm.nih.gov/pubmed/28293555
http://dx.doi.org/10.3389/fmed.2017.00013
_version_ 1782510975241420800
author Corrales, Luis
Nogueira, Amanda
Passiglia, Francesco
Listi, Angela
Caglevic, Christian
Giallombardo, Marco
Raez, Luis
Santos, Edgardo
Rolfo, Christian
author_facet Corrales, Luis
Nogueira, Amanda
Passiglia, Francesco
Listi, Angela
Caglevic, Christian
Giallombardo, Marco
Raez, Luis
Santos, Edgardo
Rolfo, Christian
author_sort Corrales, Luis
collection PubMed
description Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors (vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor). Several preclinical and clinical studies have proven the usefulness of nintedanib as an anticancer agent for NSCLC. The most important study was the phase III LUME-Lung 1 trial, which investigated the combination of nintedanib with docetaxel for second-line treatment in advanced NSCLC patients. The significant improvement in overall survival and the manageable safety profile led to the approval of this new treatment in Europe. This review focuses on the preclinical and clinical studies with nintedanib in NSCLC.
format Online
Article
Text
id pubmed-5329017
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-53290172017-03-14 Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib Corrales, Luis Nogueira, Amanda Passiglia, Francesco Listi, Angela Caglevic, Christian Giallombardo, Marco Raez, Luis Santos, Edgardo Rolfo, Christian Front Med (Lausanne) Medicine Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors (vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor). Several preclinical and clinical studies have proven the usefulness of nintedanib as an anticancer agent for NSCLC. The most important study was the phase III LUME-Lung 1 trial, which investigated the combination of nintedanib with docetaxel for second-line treatment in advanced NSCLC patients. The significant improvement in overall survival and the manageable safety profile led to the approval of this new treatment in Europe. This review focuses on the preclinical and clinical studies with nintedanib in NSCLC. Frontiers Media S.A. 2017-02-28 /pmc/articles/PMC5329017/ /pubmed/28293555 http://dx.doi.org/10.3389/fmed.2017.00013 Text en Copyright © 2017 Corrales, Nogueira, Passiglia, Listi, Caglevic, Giallombardo, Raez, Santos and Rolfo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Corrales, Luis
Nogueira, Amanda
Passiglia, Francesco
Listi, Angela
Caglevic, Christian
Giallombardo, Marco
Raez, Luis
Santos, Edgardo
Rolfo, Christian
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
title Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
title_full Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
title_fullStr Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
title_full_unstemmed Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
title_short Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
title_sort second-line treatment of non-small cell lung cancer: clinical, pathological, and molecular aspects of nintedanib
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329017/
https://www.ncbi.nlm.nih.gov/pubmed/28293555
http://dx.doi.org/10.3389/fmed.2017.00013
work_keys_str_mv AT corralesluis secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT nogueiraamanda secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT passigliafrancesco secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT listiangela secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT caglevicchristian secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT giallombardomarco secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT raezluis secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT santosedgardo secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib
AT rolfochristian secondlinetreatmentofnonsmallcelllungcancerclinicalpathologicalandmolecularaspectsofnintedanib